MicroPort Endovascular MedTech Ltd (688016) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.012x

Based on the latest financial reports, MicroPort Endovascular MedTech Ltd (688016) has a cash flow conversion efficiency ratio of 0.012x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥46.79 Million ≈ $6.85 Million USD) by net assets (CN¥3.98 Billion ≈ $582.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 688016 market cap for the company's overall valuation and market capitalisation.

MicroPort Endovascular MedTech Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how MicroPort Endovascular MedTech Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

MicroPort Endovascular MedTech Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of MicroPort Endovascular MedTech Ltd ranked by their cash flow conversion efficiency. Explore MicroPort Endovascular MedTech Ltd cash flow quality index to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Global Ship Lease Inc
NYSE:GSL
0.065x
Anhui Xinhua Media Co Ltd
SHG:601801
-0.036x
YFY Inc
TW:1907
0.018x
Flight Centre Travel Group Ltd
AU:FLT
-0.051x
ICF International Inc
NASDAQ:ICFI
0.095x
First Tractor Co Ltd
SHG:601038
-0.009x
IGNITIS GRUPE AB EO 2233
F:IGV0
0.048x
Pavilion Real Estate Inv Trust
KLSE:5212
0.098x

Annual Cash Flow Conversion Efficiency for MicroPort Endovascular MedTech Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of MicroPort Endovascular MedTech Ltd from 2016 to 2025. View 688016 stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CN¥8.62 Billion
≈ $1.26 Billion
CN¥573.06 Million
≈ $83.86 Million
0.066x -32.01%
2024-12-31 CN¥3.82 Billion
≈ $559.35 Million
CN¥373.60 Million
≈ $54.67 Million
0.098x -33.89%
2023-12-31 CN¥3.86 Billion
≈ $565.36 Million
CN¥571.22 Million
≈ $83.59 Million
0.148x -22.81%
2022-12-31 CN¥1.74 Billion
≈ $255.00 Million
CN¥333.76 Million
≈ $48.84 Million
0.192x -2.91%
2021-12-31 CN¥1.52 Billion
≈ $222.73 Million
CN¥300.25 Million
≈ $43.94 Million
0.197x +11.95%
2020-12-31 CN¥1.23 Billion
≈ $180.57 Million
CN¥217.44 Million
≈ $31.82 Million
0.176x +31.17%
2019-12-31 CN¥1.07 Billion
≈ $155.98 Million
CN¥143.20 Million
≈ $20.96 Million
0.134x -72.82%
2018-12-31 CN¥216.16 Million
≈ $31.63 Million
CN¥106.85 Million
≈ $15.64 Million
0.494x +34.01%
2017-12-31 CN¥188.02 Million
≈ $27.51 Million
CN¥69.36 Million
≈ $10.15 Million
0.369x +51.03%
2016-12-31 CN¥123.38 Million
≈ $18.05 Million
CN¥30.13 Million
≈ $4.41 Million
0.244x --

About MicroPort Endovascular MedTech Ltd

SHG:688016 China Medical Devices
Market Cap
$1.53 Billion
CN¥10.45 Billion CNY
Market Cap Rank
#7209 Global
#1548 in China
Share Price
CN¥84.76
Change (1 day)
+0.72%
52-Week Range
CN¥83.14 - CN¥112.72
All Time High
CN¥443.37
About

Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft syste… Read more